Phreesia Earnings Call Transcripts
Fiscal Year 2026
-
Fiscal 2026 saw record Adjusted EBITDA, free cash flow, and first-ever positive GAAP net income, driven by AccessOne and operational efficiency. FY27 revenue guidance was lowered due to pharma spending headwinds, but margin and cash flow outlooks remain strong.
-
Q3 delivered 13% revenue growth and record margins, with strong cash flow and positive net income. The AccessOne acquisition expands provider financing capabilities, while new HCP marketing initiatives and AI-driven solutions are set to drive future growth.
-
Q2 FY2026 saw 15% revenue growth, first-ever positive net income, and a $160M AccessOne acquisition to expand the addressable market by $6B. Adjusted EBITDA margin reached 19%, and new AI products are driving strong engagement and future growth.
-
Revenue rose 15% year-over-year to $115.9M, with adjusted EBITDA up 16.7% and strong cash flow. FY2026 guidance was raised for adjusted EBITDA, and a share repurchase plan was authorized. Product innovation and AI integration continue to drive growth.
Fiscal Year 2025
-
Q4 revenue grew 15% year-over-year to $109.7M, with adjusted EBITDA of $16.4M and strong cash flow. Fiscal 2026 guidance is maintained, with continued growth in clients and per-client revenue expected. AI and new product rollouts are driving operational leverage and market differentiation.
-
Q3 FY2025 saw 17% revenue growth and strong margin expansion, with positive cash flow and a raised FY2025 Adjusted EBITDA outlook. FY2026 guidance projects 13–15% revenue growth and over 129% Adjusted EBITDA growth, supported by disciplined expense management and expanding client base.
-
Q2 2025 saw 19% revenue growth, record positive free cash flow, and raised EBITDA guidance. Network solutions and larger deal sizes are driving future growth, with strong retention and continued investment in product and sales.